Bohemia Pharmaceuticals

Bohemia Pharmaceuticals is a biotechnology company based in the Czech Republic that specializes in the development and manufacturing of bacteriophage therapies and bacterial lysates. The company is notably recognized for producing Stafal, a registered antistaphylococcal phage lysate used to treat infections caused by Staphylococcus aureus, including multidrug-resistant strains like MRSA. Operating under EU Good Manufacturing Practice (GMP) standards, Bohemia Pharmaceuticals utilizes its proprietary phage technology platform to create targeted alternatives to conventional antibiotics. The company has historically collaborated with Masaryk University and has received support from European structural funds for its research into next-generation vaccines, such as a novel pertussis candidate. In recent years, the company's operations and product portfolio, including Stafal, have been closely integrated with or transitioned to AUMED s.r.o., which now oversees its commercial and R&D activities.